{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:15:24Z","timestamp":1792541724507,"version":"4.5.0"},"reference-count":49,"publisher":"American Medical Association (AMA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Psychiatry"],"published-print":{"date-parts":[[2024,6,1]]},"abstract":"<jats:sec id=\"ab-ysc240001-1\"><jats:title>Importance<\/jats:title><jats:p>Interest in administering psychedelic agents as mental health treatment is growing rapidly. As drugmakers invest in developing psychedelic medicines for several psychiatric indications, lawmakers are enacting legal reforms to speed access globally, and health agencies are preparing to approve these treatments. Meanwhile, US states, such as Oregon and Colorado, are making psychedelics available for supervised use outside the conventional health care system.<\/jats:p><\/jats:sec><jats:sec id=\"ab-ysc240001-2\"><jats:title>Observations<\/jats:title><jats:p>Despite legal change and potentially imminent regulatory approval in some countries, standards for integrating psychedelics into health care have lagged, including norms for designing and implementing informed consent processes. Informed consent is complicated by the unique features of psychedelics and their means of administration. Because no governments have approved any classic psychedelics for general medical or psychiatric use, only clinical researchers have obtained informed consent from trial participants. Accordingly, there is an unmet need for informed consent processes tailored to the challenges of administering psychedelics in nonresearch settings.<\/jats:p><\/jats:sec><jats:sec id=\"ab-ysc240001-3\"><jats:title>Conclusions and Relevance<\/jats:title><jats:p>Analysis of the challenges of designing and implementing psychedelic informed consent practices revealed 7 essential components, including the possibility of short- and long-term perceptual disturbances, potential personality changes and altered metaphysical beliefs, the limited role of reassuring physical touch, the potential for patient abuse or coercion, the role and risks of data collection, relevant practitioner disclosures, and interactive patient education and comprehension assessment. Because publicly available informed consent documents for psychedelic clinical trials often overlook or underemphasize these essential elements, sample language and procedures to fill the gap are proposed.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamapsychiatry.2024.0184","type":"journal-article","created":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T15:00:56Z","timestamp":1712761256000},"page":"611","source":"Crossref","is-referenced-by-count":55,"title":["Essentials of Informed Consent to Psychedelic Medicine"],"prefix":"10.1001","volume":"81","author":[{"given":"Mason","family":"Marks","sequence":"first","affiliation":[{"name":"Project on Psychedelics Law and Regulation (POPLAR), Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics, Harvard Law School, Cambridge, Massachusetts"},{"name":"Florida State University College of Law, Tallahassee, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca W.","family":"Brendel","sequence":"additional","affiliation":[{"name":"Center for Bioethics, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmel","family":"Shachar","sequence":"additional","affiliation":[{"name":"Center for Health Law and Policy Innovation, Harvard Law School, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I. Glenn","family":"Cohen","sequence":"additional","affiliation":[{"name":"Project on Psychedelics Law and Regulation (POPLAR), Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics, Harvard Law School, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"10","key":"ysc240001r1","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1038\/s41591-021-01530-3","article-title":"Psychedelic therapy: a roadmap for wider acceptance and utilization.","volume":"27","author":"Marks","year":"2021","journal-title":"Nat Med"},{"issue":"10","key":"ysc240001r2","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1038\/s41386-023-01648-7","article-title":"Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication.","volume":"48","author":"Goodwin","year":"2023","journal-title":"Neuropsychopharmacology"},{"key":"ysc240001r3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2022.120302","article-title":"Review of potential psychedelic treatments for PTSD.","volume":"439","author":"Henner","year":"2022","journal-title":"J Neurol Sci"},{"key":"ysc240001r4","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1080\/13284207.2022.2086793","article-title":"Reduced death anxiety and obsessive beliefs as mediators of the therapeutic effects of psychedelics on obsessive compulsive disorder symptomology.","volume":"27","author":"Moreton","year":"2022","journal-title":"Clin Psychol"},{"key":"ysc240001r5","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2023.1183740","article-title":"Psychedelic therapy in the treatment of addiction: the past, present and future.","volume":"14","author":"Zafar","year":"2023","journal-title":"Front Psychiatry"},{"issue":"19","key":"ysc240001r7","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1056\/NEJMp2308940","article-title":"How should the FDA evaluate psychedelic medicine?","volume":"389","author":"Marks","year":"2023","journal-title":"N Engl J Med"},{"key":"ysc240001r10","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2022.109399","article-title":"The varieties of psychedelic law.","volume":"226","author":"Marks","year":"2023","journal-title":"Neuropharmacology"},{"issue":"1","key":"ysc240001r11","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s13063-020-04969-w","article-title":"The reality of informed consent: empirical studies on patient comprehension-systematic review.","volume":"22","author":"Pietrzykowski","year":"2021","journal-title":"Trials"},{"issue":"19","key":"ysc240001r12","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1001\/jama.2016.3070","article-title":"The new era of informed consent: getting to a reasonable-patient standard through shared decision making.","volume":"315","author":"Spatz","year":"2016","journal-title":"JAMA"},{"issue":"6","key":"ysc240001r13","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1016\/j.amjsurg.2017.09.015","article-title":"Informed consent\u2014it\u2019s more than a signature on a piece of paper.","volume":"214","author":"Cocanour","year":"2017","journal-title":"Am J Surg"},{"key":"ysc240001r14","doi-asserted-by":"publisher","DOI":"10.1556\/2054.2023.00267","article-title":"Altered stakes. Identifying gaps in the informed consent process for psychedelic-assisted therapy trials.","author":"Harrison","year":"2023","journal-title":"J Psychedelic Stud"},{"issue":"2","key":"ysc240001r15","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1038\/s41591-022-02169-4","article-title":"Drug scheduling limits access to essential medicines and should be reformed.","volume":"29","author":"Marks","year":"2023","journal-title":"Nat Med"},{"issue":"9","key":"ysc240001r16","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1001\/jama.2023.14530","article-title":"Single-dose psilocybin treatment for major depressive disorder: a randomized clinical trial.","volume":"330","author":"Raison","year":"2023","journal-title":"JAMA"},{"key":"ysc240001r18","doi-asserted-by":"publisher","first-page":"100","DOI":"10.3389\/fphar.2018.00100","article-title":"Clinical interpretations of patient experience in a trial of psilocybin-assisted psychotherapy for alcohol use disorder.","volume":"9","author":"Bogenschutz","year":"2018","journal-title":"Front Pharmacol"},{"key":"ysc240001r19","doi-asserted-by":"publisher","first-page":"22166","DOI":"10.1038\/s41598-021-01209-2","article-title":"Psychedelics alter metaphysical beliefs.","volume":"11","author":"Timmermann","year":"2021","journal-title":"Sci Rep"},{"issue":"4","key":"ysc240001r20","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1007\/s00213-011-2358-5","article-title":"Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects.","volume":"218","author":"Griffiths","year":"2011","journal-title":"Psychopharmacology (Berl)"},{"issue":"18","key":"ysc240001r21","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1056\/NEJMoa2206443","article-title":"Single-dose psilocybin for a treatment-resistant episode of major depression.","volume":"387","author":"Goodwin","year":"2022","journal-title":"N Engl J Med"},{"issue":"6","key":"ysc240001r22","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1038\/s41591-021-01336-3","article-title":"MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study.","volume":"27","author":"Mitchell","year":"2021","journal-title":"Nat Med"},{"key":"ysc240001r23","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.878609","article-title":"Hallucinogenic persisting perception disorder: a case series and review of the literature.","volume":"13","author":"Ford","year":"2022","journal-title":"Front Neurol"},{"issue":"4","key":"ysc240001r24","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1080\/02791072.2022.2129885","article-title":"Predictors of psychedelic experience: a thematic analysis.","volume":"55","author":"McCartney","year":"2023","journal-title":"J Psychoactive Drugs"},{"key":"ysc240001r25","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.jad.2023.01.073","article-title":"Prevalence and associations of challenging, difficult or distressing experiences using classic psychedelics.","volume":"326","author":"Simonsson","year":"2023","journal-title":"J Affect Disord"},{"issue":"3","key":"ysc240001r29","doi-asserted-by":"publisher","first-page":"387","DOI":"10.3390\/neurolint13030038","article-title":"Selective serotonin reuptake inhibitors and adverse events: a narrative review.","volume":"13","author":"Edinoff","year":"2021","journal-title":"Neurol Int"},{"issue":"4","key":"ysc240001r30","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1001\/jama.2020.22106","article-title":"Balancing the risks and benefits of benzodiazepines.","volume":"325","author":"Hirschtritt","year":"2021","journal-title":"JAMA"},{"issue":"S1","key":"ysc240001r31","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1192\/j.eurpsy.2022.470","article-title":"Role of nurses in the initiation and monitoring of lithium.","volume":"65","author":"Moalla","year":"2022","journal-title":"Eur Psychiatry"},{"issue":"11","key":"ysc240001r32","doi-asserted-by":"publisher","first-page":"3393","DOI":"10.1007\/s00213-022-06241-2","article-title":"A systematic review on the use of clozapine in treatment of tardive dyskinesia and tardive dystonia in patients with psychiatric disorders.","volume":"239","author":"Wong","year":"2022","journal-title":"Psychopharmacology (Berl)"},{"issue":"9","key":"ysc240001r33","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1177\/0269881120916143","article-title":"Survey of entity encounter experiences occasioned by inhaled N,N-dimethyltryptamine: phenomenology, interpretation, and enduring effects.","volume":"34","author":"Davis","year":"2020","journal-title":"J Psychopharmacol"},{"key":"ysc240001r34","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/978-3-662-55880-5","article-title":"A review of hallucinogen persisting perception disorder (HPPD) and an exploratory study of subjects claiming symptoms of HPPD.","volume":"36","author":"Halpern","year":"2018","journal-title":"Curr Top Behav Neurosci"},{"key":"ysc240001r35","doi-asserted-by":"publisher","first-page":"258","DOI":"10.3389\/fnbeh.2018.00258","article-title":"Treating PTSD: a review of evidence-based psychotherapy interventions.","volume":"12","author":"Watkins","year":"2018","journal-title":"Front Behav Neurosci"},{"issue":"S1","key":"ysc240001r36","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s12152-019-09419-2","article-title":"Changes in personality associated with deep brain stimulation: a qualitative evaluation of clinician perspectives.","volume":"14","author":"Thomson","year":"2021","journal-title":"Neuroethics"},{"key":"ysc240001r37","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyg.2021.643277","article-title":"Does personality change follow deep brain stimulation in Parkinson\u2019s disease patients?","volume":"12","author":"Wilt","year":"2021","journal-title":"Front Psychol"},{"issue":"8","key":"ysc240001r38","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1001\/jamapsychiatry.2023.1031","article-title":"Extrapharmacological safety topics in psychedelic-assisted psychotherapy.","volume":"80","author":"Calder","year":"2023","journal-title":"JAMA Psychiatry"},{"issue":"1","key":"ysc240001r39","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s10508-018-1238-z","article-title":"The importance of studying consent and consent violations in collective sex environments.","volume":"48","author":"Lehmiller","year":"2019","journal-title":"Arch Sex Behav"},{"key":"ysc240001r44","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.3389\/fpsyg.2020.01681","article-title":"Psychedelic research and the need for transparency: polishing Alice\u2019s looking glass.","volume":"11","author":"Petranker","year":"2020","journal-title":"Front Psychol"},{"issue":"1","key":"ysc240001r45","article-title":"The challenges of informed consent in high-stakes, randomized oncology trials.","volume":"4","author":"Nath","year":"2019","journal-title":"Syst Rev"},{"issue":"1","key":"ysc240001r46","doi-asserted-by":"publisher","first-page":"4027","DOI":"10.1038\/s41598-022-08047-w","article-title":"Simulated visual hallucinations in virtual reality enhance cognitive flexibility.","volume":"12","author":"Rastelli","year":"2022","journal-title":"Sci Rep"},{"issue":"1","key":"ysc240001r47","doi-asserted-by":"publisher","DOI":"10.1080\/20008198.2019.1654782","article-title":"Virtual reality exposure therapy for posttraumatic stress disorder (PTSD): a meta-analysis.","volume":"10","author":"Kothgassner","year":"2019","journal-title":"Eur J Psychotraumatol"},{"key":"ysc240001r48","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.733584","article-title":"The effect of virtual reality on emotional response and symptoms provocation in patients with OCD: a systematic review and meta-analysis.","volume":"12","author":"Dehghan","year":"2022","journal-title":"Front Psychiatry"},{"issue":"17","key":"ysc240001r49","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1080\/10447318.2020.1778351","article-title":"Virtual reality sickness.","volume":"36","author":"Chang","year":"2020","journal-title":"Int J Hum Comput Interact"},{"key":"ysc240001r17","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/7854_2016_459","volume-title":"Behavioral Neurobiology of Psychedelic Drugs","author":"Preller","year":"2016"},{"key":"ysc240001r6","unstructured":"Rough E, Garratt K, Sutherland N. Debate on access to psilocybin treatment. House of Commons Library. Published May 17, 2023. Accessed September 6, 2023. https:\/\/researchbriefings.files.parliament.uk\/documents\/CDP-2023-0108\/CDP-2023-0108.pdf"},{"key":"ysc240001r8","unstructured":"Change to classification of psilocybin and MDMA to enable prescribing by authorized psychiatrists. Australian Therapeutic Goods Administration. Published February 3, 2023. Accessed September 6, 2023. https:\/\/www.tga.gov.au\/news\/media-releases\/change-classification-psilocybin-and-mdma-enable-prescribing-authorised-psychiatrists"},{"key":"ysc240001r9","unstructured":"Herrington? AJ. Quebec approves health coverage for psilocybin therapy. Forbes. December 16, 2022. Accessed January 28, 2016. https:\/\/www.forbes.com\/sites\/ajherrington\/2022\/12\/16\/quebec-approves-health-coverage-for-psilocybin-therapy\/?sh=3cc9c4e17fa9"},{"key":"ysc240001r26","unstructured":"Smith? DG. What does good psychedelic therapy look like? New York Times. June 3, 2023. Accessed September 6, 2023. https:\/\/www.nytimes.com\/2023\/06\/03\/well\/mind\/psychedelic-therapy.html"},{"key":"ysc240001r27","unstructured":"Rosin? H. You won\u2019t feel high after watching this video. The Cut. March 22, 2022. Accessed September 6, 2023. https:\/\/www.thecut.com\/2022\/03\/you-wont-feel-high-after-watching-this-video.html"},{"key":"ysc240001r28","unstructured":"Goldhill? O. A psychedelic therapist allegedly took millions from a Holocaust survivor, highlighting worries about elders taking hallucinogens. STAT. April 21, 2022. Accessed September 6, 2023. https:\/\/www.statnews.com\/2022\/04\/21\/psychedelic-therapist-allegedly-took-millions-from-holocaust-survivor-highlighting-worries-about-elders-taking-hallucinogens\/"},{"key":"ysc240001r40","unstructured":"Oladipo? G. Green for hugs, red for no touching: US events introduce pandemic color coding. The Guardian. June 10, 2021. Accessed September 6, 2023. https:\/\/www.theguardian.com\/us-news\/2021\/jun\/10\/color-coded-accessories-pandemic-boundaries."},{"key":"ysc240001r41","unstructured":"MacBridge? K. Aharon said it was healing. Inverse. November 16, 2021. Accessed September 6, 2023. https:\/\/www.inverse.com\/mind-body\/grossbard-bourzat-psychedelic-assisted-therapy-abuse"},{"key":"ysc240001r42","unstructured":"Marks? M. Seeking psychedelics? check the data privacy clause. Wired. November 2, 2022. Accessed September 6, 2023. https:\/\/www.wired.com\/story\/colorado-psychedelics-health-privacy-surveillance\/"},{"key":"ysc240001r43","unstructured":"Alltucker? K, Pallaro? B. Hacks on hospital records are surging. here\u2019s why your medical data is vulnerable. USA Today. March 13, 2023. Accessed September 6, 2023. https:\/\/www.usatoday.com\/story\/news\/health\/2023\/03\/13\/data-breaches-surge-medical-info-vulnerable-hackers\/11365907002\/"}],"container-title":["JAMA Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/articlepdf\/2817593\/jamapsychiatry_marks_2024_sc_240001_1716936097.52904.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T16:18:47Z","timestamp":1717604327000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/fullarticle\/2817593"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,1]]},"references-count":49,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamapsychiatry.2024.0184","relation":{},"ISSN":["2168-622X"],"issn-type":[{"value":"2168-622X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6,1]]}}}